ISRCTN72521486进行中（未招募）3 期
eoadjuvant chemotherapy with pyrotinib, trastuzumab, docetaxel, and carboplatin in combination for locally advanced human epidermal growth factor receptor 2-positive breast cancer: a multicenter, randomized, open-label, parallel-group controlled phase III trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 532
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Female breast cancer patients at the age of = 18 years and = 65 years who received first treatment
- •2. ECOG (Eastern Cooperative Oncology Group) score of 0 or 1
- •3. Histologically confirmed invasive breast cancer with a primary tumor diameter of more than 2 cm; TNM staging T2-3, N2 or N3, M0
- •4. Pathologically confirmed HER2-positive breast cancer, which is defined as the immunohistochemistry score of > 10% immunoreactive cells being 3+ or in situ hybridization results showing HER2 gene amplification
- •5. Known state of hormone receptors and progesterone receptor is known
- •6. The functional level of the main organs must meet the following requirements (no blood transfusion and no use of leukocytes- and platelets-raising drugs in 2 weeks before screening): absolute neutrophil count (ANC) = 1.5 × 109/L, platelet (PLT) count = 90 × 109/L, hemoglobin (Hb) = 90 g/L, total bilirubin (TBIL) = upper limits of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 1.5 × ULN, alkaline phosphatase = 2.5 x ULN, blood urea nitrate (BUN) and creatinine (Cr) < 1.5 × ULN, left ventricular ejection fractions (LVEF) > 55%, corrected QT interval by Fredericia (QTcF) < 470 ms
- •7. For women who are not menopausal or who have not undergone surgical sterilization, they agree to stay abstinent or use effective contraceptive methods during the whole treatment period and for at least 7 months after the last administration during the study period
- •8. Volunteer to participate in the study; provision of written informed consent; good compliance and willing to cooperate during the follow-up
排除标准
- •1. Stage IV (metastatic) breast cancer
- •2. Patients who had received antineoplastic therapy or radiotherapy for any malignant tumors, but excluding cured cervical cancer in situ, basal cell carcinoma or squamous cell carcinoma
- •3. Patients who are receiving anti-cancer therapy in other clinical trials, including endocrine therapy, bisphosphonate therapy or immunotherapy
- •4. Those who had undergone major breast cancer-free operations within 4 weeks before randomization or who had not yet fully recovered from such surgeries
- •5. Severe cardiac diseases or discomforts
- •6. Inability to swallow, intestinal obstruction or other factors affecting drug use and absorption
- •7. Anyone with known history of allergy to the components of study drugs; history of immunodeficiency, or other acquired or congenital immunodeficiency disorders, or history of organ transplantation
- •8. Female patients during pregnancy and lactation, those with fertility and providing positive baseline pregnancy test results, or those of childbearing age who are unwilling to take effective contraceptive measures throughout the trial
- •9. Patients with severe concomitant diseases or other complications that interfere with planned treatment or in any other case considered unsuitable by the researchers to participate in the study
研究者
相似试验
Unknown
2 期
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast CancerBreast CancerNCT04717531The First Affiliated Hospital with Nanjing Medical University60
进行中（未招募）
2 期
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerBreast CancerNCT04290793Hebei Medical University Fourth Hospital113
尚未招募
不适用
eoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 studyBreast cancerNL-OMON53609Antoni van Leeuwenhoek Ziekenhuis30
已完成
不适用
Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer PatientsBreast CancerNCT05839288Fudan University161
尚未招募
Unknown
eoadjuvant lazertinib with or without chemotherapy for patients with EGFR-mutated resectable non-small cell lung cancer (NeoLazer): a phase II, randomized, multi-center studyNeoplasmsKCT0009313Yonsei University Health System, Severance Hospital160